Articles tagged with Epilepsy
Adults with both epilepsy and hearing loss who use hearing aids have a 23% lower risk of developing dementia. The association was observed consistently across all analyses, suggesting that correcting hearing impairment may have a greater impact on dementia risk in people with reduced cognitive reserve.
A new EPI-SLEEP study will investigate the impact of personalized in-ear sleep technology on sleep disturbances and circadian health in adults with epilepsy. The study aims to generate robust evidence for a low-risk approach to improving sleep without adding medication burden.
Researchers will investigate the link between SYNGAP1 protein deficiency, cilia dysfunction, and clinical symptoms of SYNGAP1-Related Disorders. The study aims to inform rational drug design and provide new insights for targeted therapies.
A study by the American Academy of Neurology found that people with epilepsy living in rural areas had poorer health outcomes, including higher mortality rates, longer hospital stays, and reduced access to specialized care. The study highlights the need for improved access to epilepsy care in rural areas.
The CURE SYNGAP1 COLLECTIVE is a collaborative framework uniting independent SYNGAP1 charities worldwide to accelerate treatments for individuals with SYNGAP1-Related Disorders. The Collective focuses on three primary pillars: research, industry engagement, and patient advocacy.
CURE SYNGAP1 invests in remote assessment tools to broaden access to clinical care and trials for patients with SYNGAP1-Related Disorders. The study aims to evaluate the validity of a standardized remote developmental assessment to reduce travel burden.
A new study found that a smartwatch application accurately detected tonic-clonic seizures in people with epilepsy, with a low rate of false alarms. The app had an overall sensitivity of 98% and was associated with fewer false alarms compared to other devices.
The 2025 Impact Report showcases tangible progress made by CURE SYNGAP1, including almost $1.8M in grants and the most successful SYNGAP1 Science Conference ever. The report highlights the organization's focus on Collaboration, Transparency, and Urgency, driving momentum for clinical trials and treatments.
CURE SYNGAP1 partners with RARE-X to accelerate ProMMiS study's Patient-Reported Outcome measure data collection. This investment enables the centralized collection of high-quality PROs, essential for regulatory approval and therapy development.
A large population-based study found that children with epilepsy have a significantly higher risk of also having autism spectrum disorder. The study highlighted key differences between children with co-occurring conditions, including intellectual disability and age of diagnosis.
Researchers suggest treatment could start during pregnancy to prevent brain damage and reduce neurological harm. A new RNA-based therapy reduces abnormal electrical currents in patient-derived excitatory neurons.
Researchers discovered that interictal epileptiform discharges (IEDs) occur in a predictable pattern, unfolding sequentially in individual neurons. Nearly 80% of IED-involving neurons are also involved in language and perception, suggesting the brain blips can derail cognition.
Researchers at UCLA mapped how Down syndrome disrupts prenatal neuron development, leading to cognitive and sensory processing differences. The study found altered developmental sequences and cell populations that may contribute to the condition's effects.
A recent study published in Neurology found that people with epilepsy who experience poor sleep are at a higher risk of developing dementia compared to those without epilepsy. Optimal sleep, defined as six to eight hours per day, is associated with better cognitive function and lower dementia risk.
NYU Langone Health experts present platform talks on practical strategies to counter medical misinformation, phase 3 X-TOLE2 trial results for novel epilepsy treatment, and exploring healthcare accessibility for patients with disabilities. The Department of Neurology features over 80 presentations from faculty members.
A new study by University College London found that gabapentinoids, prescribed for chronic pain, double the risk of hospitalization for drug poisoning when combined with benzodiazepines or opioids. The risk persists even after starting gabapentinoid treatment, suggesting they may not be an effective solution to reduce poisoning risks.
A large Nordic register-based study finds that high-dose folic acid supplementation before pregnancy reduces the risk of major congenital anomalies by 45% in women taking antiseizure medication. Starting folic acid after pregnancy onset has no protective effect.
The organization welcomes Craig Bower, Allison Hirsch Hadar, Susan Johnson, Andrew Schillaci, and Ed Warshauer to its Board of Trustees, succeeding outgoing members. These new leaders join a mission primed for global impact, signaling a reinforced commitment to accelerating safe, effective, and targeted therapies.
Researchers used base editing to correct the SCN8A gene mutation responsible for severe inherited epilepsy. The approach successfully eliminated or reduced seizures and improved brain function in lab mice, offering new hope for treating genetic epilepsies.
CURE SYNGAP1 accelerates treatment development for SYNGAP1-Related Disorders through rigorous research and family-led leadership. The organization has funded over $8 million in grants and identified over 1,707 patients to date.
Research reveals associations between antiseizure drugs and neurodevelopmental disorders in children, with valproate and zonisamide linked to increased risks. The study highlights the need for continued monitoring of new antiseizure drugs and further evaluation of their safety during pregnancy.
A new review outlines the scientific explanations behind ketogenic diets' therapeutic benefits for epilepsy, including their ability to strengthen brain energy systems, reduce inflammation, and protect neurons. The review highlights the need for further research, particularly in adults, to develop new therapies that mirror the diet's e...
Researchers developed a new noninvasive brain stimulation technique by combining focused ultrasound with electrical stimulation, producing stronger, targeted brain responses. This approach, called transcranial electro-acoustic stimulation, clarifies conflicting results in the field and introduces a new approach to noninvasive brain sti...
A mini-review synthesizes large-scale genomic findings to illuminate the polygenic architecture underlying common epilepsies. Rare genetic variants contribute to epilepsy risk, with shared biological pathways involving ion channel function and synaptic excitability
Researchers discovered that FOXJ3 gene mutations disrupt brain layer formation, leading to drug-resistant epilepsy. The study reveals a critical link between abnormal brain development and epilepsy, identifying FOXJ3 as a key genetic and molecular cause.
Mayo Clinic researchers have identified a hidden 'movement map' deep within the brain, which could help surgeons reduce side effects from epilepsy procedures and guide future treatments for speech and movement disorders. The discovery was made using advanced brain-recording technology to create individualized maps of patients' brains.
A new medication called zorevunersen has been found to reduce seizures in children with Dravet syndrome by up to 91%, improving their quality of life and behavior. The study, led by University College London and Great Ormond Street Hospital, also showed the potential to reduce the impact of the condition on mental processes.
Phase 1/2a clinical trials demonstrate significant seizure reduction and improvement in symptoms of Dravet syndrome, a genetic disorder affecting cognitive function, motor skills, and behavior. The treatment, zorevunersen, targets the underlying cause of the disease by enhancing the normal SCN1A gene.
Potassium KCNQ2/3 channels need full functionality to work properly in the brain and reach their correct location. This is linked to their regulation by protein ankG. Altering channel functionality affects neuronal excitability and may contribute to developing new therapeutic strategies for epilepsy.
Dr. Dennis Lal has been appointed as the new executive director of the Center for Innovation in Health Informatics at UT Arlington, succeeding Marion Ball. He will lead initiatives on precision health, clinical AI, and health care-scale informatics.
A ketogenic diet causes physical changes in brain cells that affect how they send information to one another, dampening the strength of signals between them. This quieter neural landscape might explain how the diet calms overactive electrical signaling characteristic of epileptic seizures.
A Mayo Clinic study found that the brain enters a deep sleep state after a seizure, mimicking memory storage and strengthening disease. This phenomenon, called seizure-related consolidation, could help explain why epilepsy worsens over time and why memory and mood problems are common in people with the condition.
Researchers created a simplified, scalable human cell model to study coordinated brain rhythms. They found that inhibitory signaling mediated by GABA helped promote sleep and prevent seizures, while potassium channel perturbations influenced rhythmic organization in distinct ways.
Rice bioengineer Jerzy Szablowski has been awarded a Sloan Research Fellowship for his innovative work on noninvasive methods to communicate with the brain. He aims to develop versatile platform technologies to obtain new types of research data and treat multiple diseases.
This systematic review compares the efficacy, safety, and quality of life outcomes associated with stereoelectroencephalography-guided temporal lobe resection (TLR) and responsive neurostimulation (RNS) in adults with drug-resistant TLE. Key findings include higher seizure freedom rates for TLR and better cognitive preservation with RNS.
Dr. Paul Donlin-Asp will investigate the molecular functions and regulation of local SYNGAP1 protein synthesis, aiming to advance therapies for SYNGAP1-related Disorders. The project seeks to map mechanisms controlling SYNGAP1 protein production in neurons.
The UTA Pediatric Brain Health and Neurosciences Center will focus on developing novel treatments for drug-resistant epilepsy in children. Dr. Papadelis' team has already made significant discoveries in identifying the epileptogenic zone and predicting surgical outcomes.
Researchers have developed a long, needle-thin brain electrode with channels that enables neural signal recording and precisely targeted medication delivery across different brain regions. The technology has primarily been developed for basic research but may be important for future treatments in epilepsy and other neurological diseases.
Dr. Àlex Bayés Puig advances SYNGAP1 research with a new SynGAP biomarker study funded by CURE SYNGAP1, enabling the detection of SYNGAP1 protein levels in blood cells. This breakthrough approach has the potential to transform diagnostics and clinical research for SYNGAP1 patients.
A new study suggests an experimental peptide, TXM-CB3, reduces recurring seizures and protects brain function in preclinical studies. Early treatment with the peptide shows significant benefits in reducing seizure activity and improving cognitive function.
A Swedish study of prematurely born adults found increased morbidity in physical and mental health, yet they reported a high quality of life. The study, which followed participants from birth to age 26-29, suggests that premature birth does not necessarily limit daily life.
Researchers at the University of Virginia Health System have discovered how the keto diet protects against epilepsy seizures by regulating brain cell activity. The team found that a specific cellular receptor, HCAR2, plays a crucial role in reducing seizures, and may be targeted for new treatments.
A new UK-wide clinical trial evaluated a self-guided behavioural sleep programme for children with epilepsy, resulting in improved sleep duration of 16.5 minutes. However, the main issue was engagement, as only half of those given access to the resources used them.
Scientists at Lund University have created a new method to directly reprogram glial cells into parvalbumin neurons, which can help regulate brain activity and potentially treat disorders such as schizophrenia and epilepsy. The breakthrough could lead to therapies that replace lost or damaged brain cells in the future.
Researchers found that eradicating aging cells in mice with a combination of dasatinib and quercetin reduced senescent cells, improved memory, and decreased seizures. The study's results suggest a potential new approach to treating temporal lobe epilepsy.
A preliminary study suggests that GLP-1 drugs, used for diabetes and weight loss, may be linked to a lower risk of developing epilepsy. Researchers found an association between the use of these drugs and a reduced risk of epilepsy, with semaglutide showing the strongest correlation.
A UK-based study found that epilepsy can be a primary cause of death in people with intellectual disabilities, with those from ethnic minorities living in the UK being particularly at risk. The research highlights significant disparities in care and service provision, calling for systemic changes to prevent avoidable deaths.
A new advance in EEG imaging technology has improved mapping for epilepsy surgery, providing an accurate and non-invasive method. Pathological HFOs were found to be the most accurate biomarker for identifying epileptogenic brain regions, allowing for precise localization of seizure onset.
The EBRAINS Summit 2025 will bring together experts to assess how neuroscience can drive medical progress, digital innovation, and responsible data use. Preliminary results from the EPINOV clinical trial, integrating virtual brain technology for epilepsy surgery planning, will be presented.
Researchers at USC have identified four distinct layers of specialized cell types in the CA1 region of the mouse hippocampus, a structure vital for memory formation. This discovery changes our understanding of how information is processed in the brain and could explain why certain cells are more vulnerable in diseases like Alzheimer's ...
A multi-institute team led by St. Jude Children's Research Hospital has discovered how certain drugs used to treat epilepsy affect their target, a membrane protein found in nearly all neurons. The study provides guidance for therapeutic optimization and sheds light on a poorly understood but therapeutically important protein.
A national study reveals the US 'epilepsy belt' regions with high incidence rates, influenced by factors like sleep habits, heat exposure, health care access, and household vehicle availability. The research offers critical insights into how epilepsy impacts older adults nationwide.
Researchers at Mayo Clinic have developed a new approach to treating drug-resistant epilepsy by mapping each patient's unique brain wave patterns. This method enables physicians to target the precise area in the brain where stimulation is most effective, moving beyond traditional one-size-fits-all treatment.
Researchers from UC San Francisco have identified the superior temporal gyrus brain region responsible for tracking words in a foreign language. The study shows that this region learns to recognize word boundaries through years of experience, enabling fluent speakers to distinguish individual words.
A nonsurgical approach has been demonstrated to quiet a specific brain circuit in an animal model by delivering engineered gene therapy only to the targeted region. The method uses low-intensity focused ultrasound to open the blood-brain barrier, allowing precise control over brain activity without impacting off-target areas.
A new contactless optical-tracking registration method has been developed to simplify robot-guided SEEG surgery, reducing positioning errors and procedure time. The study demonstrates the accuracy and ease of use of this technique, making it a promising innovation in neurosurgery.